ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements
Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.
Venus Remedies Ltd announced the appointment and re-appointment of several Directors, including Executive and Independent Directors, following approval at its 37th Annual General Meeting.
Venus Remedies Ltd held its 37th Annual General Meeting on August 20, 2026, via video conferencing. The meeting addressed ordinary and special resolutions regarding company business.
Venus Remedies informed the exchanges about their social media communications regarding a special window for re-lodgement of physical share transfer requests.
Venus Remedies Ltd announced its 37th Annual General Meeting scheduled for August 20, 2026, to consider financial statements, dividends, and director re-appointments.
Venus Remedies Ltd reported revenue from operations of ₹178.9 Cr (+30.4% YoY) and net profit of ₹23 Cr (+139.6% YoY) for Q1 FY27.
Venus Remedies will hold a board meeting on July 20, 2026. The board will consider and approve unaudited financial results for the June quarter.
Venus Remedies secured the renewal of its DSIR in-house R&D recognition for its research center. The certification supports ongoing development of novel antimicrobial resistance treatments.
Venus Remedies appointed Saransh Chaudhary and Gurminder Singh Bedi to its Board. It also re-appointed Manu Chaudhary and Savita Gupta, strengthening leadership for five-year terms.
Venus Remedies approved several board appointments, including Saransh Chaudhary as Executive Director. These leadership changes aim to strengthen governance and strategic oversight for five-year terms.
Venus Remedies recommended a ₹10 final dividend for the financial year 2025-26. The record date is August 7, 2026, with payment expected by September 18.
Venus Remedies Ltd reported revenue from operations of ₹259.4 Cr (+31.2% YoY) and net profit of ₹47.5 Cr (+126.2% YoY) for Q4 FY26.
Venus Remedies reported annual consolidated total income of ₹782.18 Crore and net profit of ₹102.78 Crore. The board recommended a 100% final dividend of ₹10 per share.
Venus Remedies received Saudi FDA approval for Plerixafor, its first global oncology marketing authorization. This grants direct access to the GCC's largest pharmaceutical market.
Venus Remedies shared social media links to encourage shareholders to update KYC details. This routine compliance effort ensures regulatory alignment and investor records accuracy.
Venus Remedies Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by P. Chadha and Associates, confirms the company's compliance with SEBI regulations and listing requirements, with no material deviations or observations reported.
Venus Remedies Limited has disclosed links to social media posts regarding a special window for the re-lodgement of physical share transfer requests. This action follows SEBI guidelines to assist shareholders in converting physical holdings.
Venus Remedies Ltd reported net profit of ₹25.6 Cr (+30.6% YoY) for Q3 FY26.
Venus Remedies Ltd has issued a social media notice regarding a special window for shareholders to re-lodge transfer requests for physical shares. This follows SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026. The announcement is a regulatory compliance update aimed at assisting shareholders with physical shareholding transitions.
Venus Remedies Limited submitted its compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026. The filing, issued by registrar MUFG Intime India, confirms that security certificates received for dematerialisation were processed and listed within prescribed timelines. This is a routine regulatory disclosure for investors.
Venus Remedies Limited's promoters and promoter group have submitted their annual disclosure under SEBI SAST Regulations for the financial year ended March 31, 2026. The promoters declared that no equity shares were encumbered or pledged during the period, providing transparency regarding the stability of promoter shareholding.